This website uses cookies. By using the website you agree to our cookie policy. You can change your cookie settings in your browser.Find out more

Dräger Hi-Flow Star HFNC Solution - HI-flow star HFNC solution in use

Dräger Hi-Flow Star HFNC Solution

Contact us

High-Flow Nasal Cannula (HFNC) Treatment

High-Flow Nasal Cannula (HFNC) Treatment is a non-invasive respiratory support therapy that delivers warm, humidified, oxygen-enriched air to patients, usually using a nasal cannula. Typically used in spontaneously breathing patients who typically require oxygen at higher flow rates. It can provide respiratory support of patients with acute hypoxemic respiratory failure and prevent subsequent intubation when used correctly. This greatly enhances patient comfort and ease of use.

Life-saving treatment with HFNC Therapy

Life-saving treatment with HFNC Therapy

Watch this video to learn more about how HFNC:

  • Leads to improvements in oxygenation1, respiratory rate2, dyspnea3 and patient comfort4
  • Helps patients recover faster following extubation1
  • Translates to improved outcomes and shorter ICU stays4

Hi-Flow Star How to use

How to use

Watch this video to learn more about how to use the Dräger Hi-Flow Star HFNC Solution HFNC.

COVID-19 Updates

According to WHO 2020, “Data from China suggests that although the majority of people with COVID-19 have a mild illness (40%) or moderate illness (40%); about 15% of them have a severe illness requiring oxygen therapy, and 5% will be critically ill requiring intensive care unit treatment.”5

"COVID-19 treatment health-care facilities should be equipped with pulse oximeters, functioning oxygen systems including single-use oxygen delivery interfaces.

Oxygen therapy is recommended for all severe and critical COVID-19 patients, with low doses ranging from 1-2 L/min in children and starting at 5 L/min in adults with nasal cannula, moderate flow rates for use with venturi mask (6-10 L/min); or higher flow rates (10-15 L/min) using a mask with reservoir bag. In addition, oxygen can be delivered at higher flow rates and in higher concentrations, using high-flow nasal cannula (HFNC) devices, non-invasive ventilation (NIV) and invasive ventilation devices.”6

Oxymixer High Flow

Dräger Hi-Flow Star HFNC Solution

A source of compressed air and oxygen as well as a gas mixer, such as the Oxymixer from Dräger, is required for operation. Caregivers will appreciate the system's simplicity. Fast setup and easy application translate to workload reduction.

The standard can be customized with the products shown below.

Draeger HI Flow Star System

HI-Flow Star

MR850 Heated Humidifier

MR850 Humidifier

Trolley

Trolley

Contact us for more info

Get in touch with us if you'd like to know more about the Dräger Hi-Flow Star HFNC Solution.

HFNC-when to use

When to use HFNC?

Recommended algorithm for high-flow nasal cannula use in acute hypoxaemic respiratory failure in immunocompetent or immunocompromised patients.

#: arterial oxygen tension (PaO2)/inspiratory oxygen fraction (FiO2) <300 (patients with arterial carbon dioxide ...

Ischaki E, Pantazopoulos I, Zakynthinos S. Nasal high flow therapy: a novel treatment rather than a more expensive oxygen device. Eur Respir Rev. 2017;26(145):170028. Published 2017 Aug 9. doi:10.1183/16000617.0028-2017

Download infographic

ROX Index

ROX Index - Predicting Success of HFNC Therapy

ROX Index ≥4.88 measured at 2, 6, or 12 hours after high-flow nasal cannula (HFNC) initiation is associated with a lower risk for intubation.

ROX Index <3.85, risk of HFNC failure is high, and intubating the patient should be discussed.

ROX Index 3.85 to <4.88, the scoring could be repeated one or two hours later for further evaluation.

PRIMARY REFERENCE
Roca, O. Messika, J. Caralt B., et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016:35:200-5.

VALIDATION
Roca O. Caralt B. Messika J. et al. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. Am J Respir Crit Care Med. 2019;199(11):1368-1376.

High-Flow Therapy literature list

Clinical evidence on High-Flow Therapy

We have prepared an interesting literature list about clinical studies, cases and reviews on High-Flow Therapy in intensive care.

Download list

Get in touch with Dräger

Contact Hospital

Draeger Arabia Co.Ltd.

P.O.Box 365642
Riyadh 11393 Kingdom of Saudi Arabia

+966 11 8288200

F: +966 11 8288222

Not all products, features, or services are for sale in all countries. Please contact your local Dräger representative for more information.

References

  1. Corley, A., Caruana, L. R., Barnett, A. G., Tronstad, O., Fraser, J. F. (2011). Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients. BJA: British Journal of Anaesthesia, Volume 107, Issue 6, December 2011, Pages 998–1004, https://doi.org/10.1093/bja/aer265
  2. Roca, O., Riera, J., Torres, F., Masclans, J.R. (2010). High-Flow Oxygen Therapy in Acute Respiratory Failure. Respiratory Care Apr 2010, 55 (4) 408-413; http://rc.rcjournal.com/content/55/4/408
  3. Sztrymf B, Messika J, Bertrand F, et al. (2011). Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med. 2011;37(11):1780-1786. doi:10.1007/s00134-011-2354-6
  4. Tiruvoipati, R., Lewis, D., Haji, K., Botha, J. (2010). High-flow nasal oxygen vs high-flow face mask: a randomized crossover trial in extubated patients. J Crit Care. 2010;25(3):463-468. doi:10.1016/j.jcrc.2009.06.050
  5. Oxygen sources and distribution for COVID-19 treatment centres; World Health Organization; 2020 (https://www.who.int/publications-detail/oxygen-sources-and-distribution-for-covid-19-treatment-centres, accessed April 2020)
  6. Clinical management of severe acute respiratory infection ( SARI ) when COVID-19 disease is suspected; Geneva: World Health Organization; 2020 (https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf, accessed 10 April 2020)